by Garth Sundem | Nov 8, 2018 | Featured, Latest News, Research
The HER2 gene is a well-known driver of breast cancer, where changes in this gene are found in about 1-in-5 cases of the disease. HER2 also contributes to about 3 percent of lung cancers, representing about 6,500 patients per year. But while drugs like trastuzumab and...
by Garth Sundem | Sep 25, 2018 | Featured, Latest News, Research
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for the Study of Lung Cancer (IASLC) World...
by Garth Sundem | Sep 24, 2018 | Featured, Latest News, Research
Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer show a...
by Taylor Abarca | Sep 12, 2018 | Featured, Patient Care
With a decade of success to increase colon cancer screening rates in Colorado, the Colorado Colorectal Screening Program is getting a facelift as the Colorado Cancer Screening Program (CCSP). In an effort to provide “whole-person cancer screening” to underserved and...
by Garth Sundem | Aug 9, 2018 | Featured, Latest News, Research
The previous decade has seen dramatic advances in the treatment of non-small cell lung cancer, as genes driving subtypes of the disease including EGFR, ALK, ROS1 and BRAF are paired with drugs that silence their action. However, a major genetic driver of non-small...
